𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Mitoxantrone and cytosine arabinoside as treatment for acute myeloblastic leukemia in older patients

✍ Scribed by P. K. MacCallum; A. Z. S. Rohatiner; C. L. Davis; J. S. Whelan; A. M. Oza; J. Lim; S. Love; J. A. L. Amess; M. Leahy; R. K. Gupta; C. G. A. Price; T. A. Lister

Publisher
Springer
Year
1995
Tongue
English
Weight
530 KB
Volume
71
Category
Article
ISSN
0939-5555

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Mitoxantrone and high-dose cytosine arab
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia
✍ Hagop M. Kantarjian; Ronald L. Walters; Michael J. Keating; Elihu H. Estey; SUSA πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 447 KB πŸ‘ 2 views

Twenty-five adult patients with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside 3 g/m2 intravenously over 2 hours every 12 hours for six doses. Overall, nine patients (36%) achieved complete

Sequential mitoxantrone, daunorubicin, a
Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia
✍ Paciucci, Paolo Alberto; Cuttner, Janet; Gottlieb, Arlan; Davis, Roger B.; Marte πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 27 KB πŸ‘ 2 views

Mitoxantrone (M) is a synthetic aminoanthraquinone with anti-leukemic activity in patients with daunorubicin (D) resistant acute leukemia. The Cancer and Leukemia Group B (CALGB) has undertaken a limited access pilot study in which M, 12 mg/m2, over 30 min, daily for 3 days, and cytosine arabinoside

Mitoxantrone and high-dose cytosine arab
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia
✍ Ronald S. Walters; Hagop M. Kantarjian; Michael J. Keating; William K. Plunkett; πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 547 KB

Forty-four patients with a diagnosis of refractory or relapsed acute myelogenous leukemia received salvage chemotherapy with high-dose cytosine arabinosine 3 g/m2 intravenously over 2 hours every 12 hours for six doses and mitoxantrone 5 mg/m2 intravenously daily for 5 days. Overall 16 patients (36%